Silicone injections: A guide and a free clinical template

Key Takeaways

Liquid silicone injections are not FDA-approved for soft-tissue augmentation, and serious complications including granulomas, migration, and pulmonary embolism are well-documented in clinical literature.

Providers must perform systematic clinical assessment of patients with silicone injection history using standardised protocols, screening for signs of migration, infection, and systemic inflammatory response.

All adverse events must be reported to FDA MedWatch; complication management is limited and outcomes variable, requiring early specialist referral for complex cases.

Pabau’s digital forms and clinical notes tools help providers document complication assessments, maintain secure patient records, and generate compliant incident reports for regulatory submission.

Download your free silicone injections clinical template

Most aesthetic practitioners and emergency providers encounter patients with a history of illicit or unregulated silicone injections at least once in their careers. The FDA has expressly warned against injectable silicone for any soft-tissue use, yet complications from undisclosed or inadequately documented injection histories remain a significant liability and safety risk.

This guide provides clinical assessment protocols, complication documentation templates, and regulatory reporting procedures that practices need to safely manage patients with silicone injection exposure. It covers what silicone injections are, why they carry serious risks, how to identify complications, and what your practice’s obligations are when adverse events occur.

Download the template below and reference it during patient intake and follow-up visits to ensure thorough documentation and regulatory compliance.

What are silicone injections?

Liquid silicone injections are a form of non-surgical soft-tissue augmentation used to add volume to the face, lips, buttocks, and breasts. The procedure involves injecting medical-grade or non-medical-grade silicone fluid directly into subcutaneous or deeper tissue layers.

The critical distinction: the FDA has never approved liquid silicone for soft-tissue augmentation in the United States. Only certain silicone-based ophthalmic devices (for retinal detachment repair) are FDA-approved. Any use of injectable silicone for cosmetic or body contouring purposes is off-label and prohibited. This legal status is critical for your documentation and patient counselling.

Why patients choose silicone injections: Cost (often significantly cheaper than FDA-approved fillers), permanence (no repeat treatments), and rapid results make illicit silicone attractive, particularly in underserved communities and among transgender and gender-nonconforming individuals seeking affordable body contouring.

Providers using digital intake forms to screen for injection history can flag patients early and develop a risk-reduction plan before complications arise.

FDA regulatory status and legal obligations

The FDA’s position is unambiguous: injectable silicone is not approved for body contouring, and its use carries serious health risks. In 2021, the FDA issued a formal warning highlighting silicone migration, granuloma formation, and systemic inflammatory reactions as documented complications.

• Legal status in the US: Injectable silicone for soft-tissue augmentation is prohibited. Practitioners who administer it face criminal liability, civil suits, and loss of licensure.
• Your role as a provider: You are not expected to treat all silicone complications-but you ARE obligated to identify silicone injection history, screen for contraindications and adverse events, counsel patients on risks, and refer to specialists when needed.
• Adverse event reporting: Any serious complication from silicone injections (including suspected cases) MUST be reported to FDA MedWatch within 30 days. Failure to report is a regulatory violation.
• Documentation requirement: Patient records must clearly document: (1) history of silicone injection exposure, (2) date/location/amount if known, (3) current signs and symptoms, (4) assessment findings, (5) referral or management plan.

Practices using integrated plastic surgery EMR software can standardise this documentation across all practitioners and ensure no adverse events slip through unreported.

Risks and complications of silicone injections

Silicone injections trigger a spectrum of complications ranging from local inflammation to life-threatening systemic reactions. Most occur weeks to years after injection. Early recognition is critical for patient safety.

Local complications

• Silicone granuloma: A foreign-body inflammatory response where the body walls off silicone with immune cells. Presents as firm nodules, may migrate, and is difficult to surgically remove without damaging surrounding tissue.
• Migration: Silicone moves from the injection site to surrounding tissues, lymph nodes, or distant organs. Causes asymmetry, disfigurement, and chronic pain.
• Infection: Non-sterile injection technique introduces bacterial pathogens. Can progress to abscess, cellulitis, or sepsis if untreated.
• Skin necrosis and scarring: Silicone can compromise blood supply, causing tissue death and permanent disfigurement.

Systemic complications

• Silicone embolism syndrome: Silicone particles enter the bloodstream and lodge in the lungs, brain, or other vital organs. Presents acutely with chest pain, dyspnoea, confusion, or stroke-like symptoms. This is a medical emergency and can be fatal.
• Chronic systemic inflammation: Silicone triggers persistent immune activation, leading to fatigue, joint pain, autoimmune-like symptoms, and elevated inflammatory markers.
• Silicone toxicity: Accumulation in organs; long-term effects are not fully understood but include immune dysfunction and fibrosis.

Complication management is limited and outcomes variable (per NIH peer-reviewed literature). Surgical removal of silicone is incomplete and high-risk. Most practitioners refer to tertiary centres or plastic surgery specialists for management.

Clinical assessment protocol for silicone injection exposure

Systematic assessment at every new patient visit flags silicone exposure and guides immediate safety decisions. Use this five-step protocol in your practice.

1. Screening question: Ask all new aesthetic patients and those with unexplained body contouring: “Have you ever had silicone, filler, or injectable treatments not done in a licensed medical setting?” Document the answer verbatim and the date.
2. History taking: If yes, obtain: approximate date, location (clinic or non-clinic), substance name if known, amount injected, any complications reported at the time, current symptoms. Use structured digital intake forms to ensure no questions are skipped.
3. Physical examination: Inspect and palpate the injection sites. Document: nodules, asymmetry, skin changes, lymphadenopathy, signs of infection. Take photographs if consent is obtained.
4. Risk stratification: Classify as low-risk (asymptomatic, no exam findings, >5 years post-injection), moderate-risk (mild local findings, no systemic symptoms), or high-risk (acute infection signs, systemic symptoms, pulmonary or neurological symptoms, embolism suspicion).
5. Management decision: Low-risk: routine monitoring, counsel on emergency warning signs. Moderate-risk: specialist referral for imaging/assessment. High-risk: emergency referral; if embolism syndrome suspected, call 911 immediately.

Maintain comprehensive patient records documenting each assessment. This record protects both the patient and your practice.

Management and referral pathways

Management depends on complication severity and organ involvement. Be prepared to escalate.

• Asymptomatic silicone exposure: Patient education on warning signs, yearly follow-up visits, no immediate intervention needed.
• Local complications (granuloma, mild infection): Refer to plastic surgery for specialist assessment. Surgical removal is partial and high-morbidity; most specialists favour conservative management with imaging surveillance.
• Suspected silicone embolism: EMERGENCY. Chest imaging (CT chest with PE protocol), cardiology and pulmonology consultation, ICU-level monitoring. Outcomes are variable; some cases resolve, others progress to multi-organ failure.
• Systemic inflammation without organ involvement: Refer to rheumatology or immunology. Anti-inflammatory management and immune monitoring may help; no curative treatment exists.

Know your local plastic surgery and emergency medicine specialists BEFORE a crisis occurs. Develop referral networks in advance.

Adverse event reporting and regulatory compliance

Failure to report silicone-injection complications to the FDA exposes your practice to regulatory sanctions, loss of licensure, and civil liability. Reporting is mandatory.

1. Define a reportable adverse event: Any serious injury, hospitalisation, disability, or suspected death associated with silicone injection. Mild local swelling alone is not reportable; infection, granuloma formation, systemic symptoms, or organ involvement are.
2. Timeline: Report within 30 days of discovery. Delayed reporting is still required-never say “it’s too late.”
3. Reporting method: File online at FDA MedWatch (medwatch.fda.gov). You will need: patient initials, date of birth, date of injection, substance name, adverse event description, and your contact information.
4. Facility reporting: If the event occurred in an accredited surgery centre or hospital, notify your facility’s compliance officer immediately. They may file a separate facility report.
5. Documentation in the medical record: Document the adverse event, your assessment, any interventions, specialist referrals, and the date and method of FDA notification. AI-assisted clinical notes can help ensure all required fields are captured consistently.

Practices using structured compliance checklists are more likely to catch reporting obligations and avoid regulatory violations.

Streamline your adverse event documentation

See how Pabau helps aesthetic practices document silicone injection exposure, flag complications early, and submit FDA reports on time.

Book a demo

Patient counselling and harm reduction documentation

Patients who have received or are considering silicone injections need clear, non-judgmental counselling on risks and alternatives. Your documentation must reflect that this conversation occurred.

Counselling talking points

• “Silicone injections are not approved by the FDA and carry serious health risks, including life-threatening complications.”
• “If you have had silicone injections in the past, we need to monitor you for complications. Early detection can prevent serious harm.”
• “Approved alternatives like hyaluronic acid fillers, fat transfer, or implants are safer and reversible if complications occur.”
• “If you experience chest pain, difficulty breathing, sudden vision changes, or numbness after injection, go to the emergency room immediately.”
• “We are here to help you access safe, regulated care. We can refer you to specialists if you need treatment for existing complications.”

Document the counselling: “Patient counselled on silicone injection risks and FDA-approved alternatives. Patient verbalised understanding. Plan: [refer / monitor / proceed with alternative treatment].”

Practices serving transgender and gender-nonconforming patients should approach this conversation with cultural humility. Acknowledge that access to affordable body contouring is genuinely limited for many, and that silicone injections represent a desperate response to real barriers-not a character flaw. Offer genuine alternatives: referrals to lower-cost specialists, information about patient assistance programmes, and harm reduction strategies if the patient is determined to proceed.

Safe, FDA-approved alternatives to silicone injections

When counselling patients, emphasise these approved options. They carry documented safety profiles and reversibility if complications occur.

• Hyaluronic acid fillers (Restylane, Juvéderm, Radiesse): FDA-approved, reversible with hyaluronidase injection, results last 6-24 months depending on formulation. Cost: $400-2,000 per syringe.
• Autologous fat transfer: Your own fat, harvested and re-injected. Permanent for retained volume; some resorption occurs. Surgical cost: $3,000-8,000.
• Silicone gel implants: FDA-approved breast implants; not suitable for all body areas but provide permanent augmentation with documented safety monitoring.
• Collagen-stimulating fillers (Sculptra): FDA-approved; stimulates your own collagen. Builds volume gradually; results last 2+ years. Cost: $800-2,000 per session (3-5 sessions typically needed).
• Specialist referral for complex body contouring: Plastic surgeons offer liposuction, implants, and tissue grafting for permanent, safe results.

Position these alternatives during cosmetic consultations as part of standard informed consent, not just for silicone-exposed patients.

Conclusion

Silicone injections carry serious, well-documented health risks-and the FDA’s regulatory warning is absolute. Your practice’s role is to screen for injection history at every visit, assess complication risk, counsel patients on alternatives, and report adverse events promptly.

The template included in this guide provides the documentation structure you need. Pair it with digital forms and integrated patient records so that no silicone-exposed patient slips through your safety net-and book a demo to see how Pabau helps you standardise this critical workflow across your team.

Continue your research

Need a framework for documenting clinical assessment findings? Med spa consultation form template provides a standardised format for capturing patient history, risk factors, and complication screening.

Want to understand adverse event management protocols? Patient care management best practices outlines follow-up workflows that catch complications before escalation.

Looking for regulatory compliance guidance? HIPAA compliance for medical offices covers patient confidentiality obligations when documenting silicone injection histories.

Frequently Asked Questions